|
CISD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62703184258817E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.02917674382752E-13 |
| Normal-vs-Stage2 |
9.90720000038081E-07 |
| Normal-vs-Stage3 |
1.75592873574715E-12 |
| Normal-vs-Stage4 |
1.63602464908763E-12 |
| Stage1-vs-Stage2 |
6.035000E-01 |
| Stage1-vs-Stage3 |
1.253200E-01 |
| Stage1-vs-Stage4 |
1.562730E-03 |
| Stage2-vs-Stage3 |
1.696960E-01 |
| Stage2-vs-Stage4 |
7.644900E-03 |
| Stage3-vs-Stage4 |
9.254300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
2.791900E-04 |
| Normal-vs-Asian |
2.1994628340849E-12 |
| Caucasian-vs-AfricanAmerican |
8.418800E-01 |
| Caucasian-vs-Asian |
5.731600E-01 |
| AfricanAmerican-vs-Asian |
6.813200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.07580611086178E-13 |
| Normal-vs-Female |
1.69086966650411E-12 |
| Male-vs-Female |
2.466800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.84718906837134E-12 |
| Normal-vs-Age(41-60Yrs) |
3.27515792264421E-14 |
| Normal-vs-Age(61-80Yrs) |
8.56881232635942E-12 |
| Normal-vs-Age(81-100Yrs) |
3.436600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.429000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.361000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.604400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.593400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.981400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.175800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.280600E-03 |
| Classical-VS-Follicular |
7.66720000000554E-05 |
| Classical-VS-Other |
3.961200E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
7.01229999622299E-08 |
| Tall-VS-Other |
8.242600E-01 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
6.808400E-02 |
| Follicular-VS-Normal |
7.439700E-04 |
| Other-VS-Normal |
3.76220000000149E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.09969999773085E-08 |
| Normal-vs-N1 |
1.66533453693773E-15 |
| N0-vs-N1 |
6.33079999999842E-05 |
|
|
